Preclinical development

Once a lead compound is identified through drug discovery, it enters preclinical development, where its safety, efficacy and pharmacological profile are evaluated. To support informed go/no-go decisions, we offer comprehensive insights into your drug candidate’s absorption, distribution, metabolism and excretion (ADME) properties. Our dedicated drug metabolism and pharmacokinetics (DMPK) team conducts a broad range of studies to characterise these properties, providing robust data to help guide development. 

Understanding a test compound’s safety profile requires not only expertise in regulatory guidelines but also the flexibility to adapt methodologies for project-specific needs, including mechanistic investigations. With decades of experience in toxicology services, we support the development of human and veterinary pharmaceuticals, as well as industrial and agrochemical products. 

Bioanalytical investigations are crucial throughout the drug development continuum, from early discovery to late-stage clinical trials. Comprehensive analysis of small and large molecules, as well as new modalities, is essential for understanding a compound's behaviour within biological systems. Nuvisan brings decades of expertise in developing, transferring and validating bioanalytical methods and analysing diverse biological matrices. 

Each step in this process helps ensure that a potential new drug candidate is both safe and effective before progressing to human trials. Through careful planning and thorough testing, we help identify and advance promising drug candidates, for the purpose of ultimately contributing to improved patient outcomes worldwide.